Pharmacokinetics and toxicity considerations for antibody–drug conjugates: an overview

References

• 1. Khongorzul P, Ling CJ, Khan FU et al. Antibody–drug conjugates: a comprehensive review. Mol. Cancer Res. 18(1), 3–19 (2020).
  Medline CASGoogle Scholar
• 2. Hedrich WD, Fandy TE, Ashour HM et al. Antibody–drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin. Pharmacokinet. 57(6), 687–703 (2018).
  Medline CASGoogle Scholar
• 3. Nejadmoghaddam M-R, Minai-Tehrani A, Ghahremanzadeh R et al. Antibody–drug conjugates: possibilities and challenges. Avicenna J. Med. Biotechnol. 11(1), 3–23 (2019).
  MedlineGoogle Scholar
• 4. Kamath AV, Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm. Res. 32(11), 3470–3479 (2015).
  Medline CASGoogle Scholar
• 5. Lucas A, Price L, Schorzman A et al. Factors affecting the pharmacology of antibody–drug conjugates. Antibodies. 7(1), 10 (2018).
  MedlineGoogle Scholar
• 6. Beaumont M, Tomazela D, Hodges D et al. Antibody–drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection. AAPS Open. 4(1), 1–17 (2018).
  Google Scholar
• 7. Kraynov E, Kamath AV, Walles M et al. Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody–drug conjugates: an industry white paper. Drug Metab. Dispos. 44(5), 617–623 (2016).
  Medline CASGoogle Scholar
• 8. Matsuda Y, Seki T, Yamada K et al. Chemical site-specific conjugation platform to improve the pharmacokinetics and therapeutic index of antibody–drug conjugates. Mol. Pharm. 18(11), 4058–4066 (2021).
  Medline CASGoogle Scholar
• 9. Matsuda Y, Kliman M, Mendelsohn BA. Application of native ion exchange mass spectrometry to intact and subunit analysis of site-specific antibody–drug conjugates produced by AJICAP first generation technology. J. Am. Soc. Mass Spectrom. 31(8), 1706–1712 (2020).
  CASGoogle Scholar
• 10. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26(8), 925–932 (2008).
  Medline CASGoogle Scholar
• 11. Mahalingaiah PK, Ciurlionis R, Durbin KR et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol. Ther. 200, 110–125 (2019).
  Medline CASGoogle Scholar
• 12. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody–drug conjugates. MAbs. 8(4), 659–671 (2016).
  Medline CASGoogle Scholar
• 13. Mou S, Huang Y, Rosenbaum A. ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody–drug conjugates. Antibodies. 7(4), 41 (2018).
  Medline CASGoogle Scholar
• 14. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. Immunochemistry. 8(9), 871–874 (1971).
  Medline CASGoogle Scholar
• 15. Kaur S, Xu K, Saad OM et al. Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics. Bioanalysis 5(2), 201–226 (2013).
  CASGoogle Scholar
• 16. Stephan JP, Kozak KR, Wong WLT. Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates. Bioanalysis 3(6), 677–700 (2011).
  CASGoogle Scholar
• 17. Li H, Ortiz R, Tran L et al. General LC–MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267–1273 (2012).
  Medline CASGoogle Scholar
• 18. Liu A, Kozhich A, Passmore D et al. Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC–MS/MS approach: Assay development, validation, and a case study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1002, 54–62 (2015).
  Medline CASGoogle Scholar
• 19. Shen B-Q, Bumbaca D, Saad O et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr. Drug Metab. 13(7), 901–910 (2012).
  Medline CASGoogle Scholar
• 20. Tang Y, Tang F, Yang Y et al. Real-time analysis on drug-antibody ratio of antibody–drug conjugates for synthesis, process optimization, and quality control. Sci. Rep. 7(1), 2–11 (2017).
  MedlineGoogle Scholar
• 21. Singh AP, Shah DK. Measurement and mathematical characterization of cell-level pharmacokinetics of antibody–drug conjugates: a case study with trastuzumab-vc-MMAE. Drug Metab. Dispos. 45(11), 1120–1132 (2017).
  Medline CASGoogle Scholar
• 22. Cahuzac H, Devel L. Analytical methods for the detection and quantification of adcs in biological matrices. Pharmaceuticals 13(12), 1–16 (2020).
  Google Scholar
• 23. Taneja N, Gota V, Gurjar M, Singh KK. Development and validation of high-performance liquid chromatographic method for quantification of irinotecan and its active metabolite SN-38 in colon tumor bearing NOD/SCID mice plasma samples: application to pharmacokinetic study. Acta Chromatogr. 31(3), 166–172 (2019).
  CASGoogle Scholar
• 24. Leal M, Wentland JA, Han X et al. Preclinical development of an anti-5T4 antibody–drug conjugate: pharmacokinetics in mice, rats, and NHP and tumor/tissue distribution in mice. Bioconjug. Chem. 26(11), 2223–2232 (2015).
  Medline CASGoogle Scholar
• 25. He J, Yu SF, Yee S et al. Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry. MAbs. 10(7), 960–967 (2018).
  Medline CASGoogle Scholar
• 26. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68(22), 9280–9290 (2008).
  MedlineGoogle Scholar
• 27. Dowell JA, Korth-Bradley J, Liu H et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41(11), 1206–1214 (2001).
  Medline CASGoogle Scholar
• 28. Scottish Medicines Consortium. Polatuzumab vedotin 140 mg powder for concentrate for solution for infusion (Polivy) (2020). www.scottishmedicines.org.uk/media/5360/polatuzumab-vedotin-polivy-final-august-2020-amended-180820-for-website.pdf
  Google Scholar
• 29. Committee for Medicinal Products for Human Use. CHMP assessment report: Enhertu (2020). www.ema.europa.eu/contact
  Google Scholar
• 30. EMA. Assessment report: Adcetris. CHMP Assess. Rep. 44, (July), 1–105 (2012).
  Google Scholar
• 31. Malik P, Phipps C, Edginton A, Blay J. Pharmacokinetic considerations for antibody–drug conjugates against cancer. Pharm. Res. 34(12), 2579–2595 (2017).
  Medline CASGoogle Scholar
• 32. Cao M, De Mel N, Jiao Y et al. Site-specific antibody–drug conjugate heterogeneity characterization and heterogeneity root cause analysis. MAbs 11(6), 1064–1076 (2019).
  Medline CASGoogle Scholar
• 33. Behrens CR, Ha EH, Chinn LL et al. Antibody–drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol. Pharm. 12(11), 3986–3998 (2015).
  Medline CASGoogle Scholar
• 34. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28(6), 507–532 (2001).
  Medline CASGoogle Scholar
• 35. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 5(1), 13–21 (2013).
  MedlineGoogle Scholar
• 36. Han TH, Zhao B. Absorption, distribution, metabolism, and excretion considerations for the development of antibody–drug conjugates. Drug Metab. Dispos. 42(11), 1914–1920 (2014).
  MedlineGoogle Scholar
• 37. Grimm HP. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J. Pharmacokinet. Pharmacodyn. 36(5), 407–420 (2009).
  Medline CASGoogle Scholar
• 38. Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. MAbs. 4(3), 362–372 (2012).
  MedlineGoogle Scholar
• 39. Brachet G, Respaud R, Arnoult C et al. Increment in drug loading on an antibody–drug conjugate increases its binding to the human neonatal Fc receptor in vitro. Mol. Pharm. 13(4), 1405–1412 (2016).
  Medline CASGoogle Scholar
• 40. Hamblett KJ, Le T, Rock BM et al. Altering antibody–drug conjugate binding to the neonatal Fc receptor impacts efficacy and tolerability. Mol. Pharm. 13(7), 2387–2396 (2016).
  Medline CASGoogle Scholar
• 41. Berger C, Madshus IH, Stang E. Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. Exp. Cell Res. 318(20), 2578–2591 (2012).
  Medline CASGoogle Scholar
• 42. Ingle GS, Chan P, Elliott JM et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br. J. Haematol. 140(1), 46–58 (2008).
  Medline CASGoogle Scholar
• 43. Williams S-P, Ogasawara A, Tinianow JN et al. ImmunoPET helps predicting the efficacy of antibody–drug conjugates targeting TENB2 and STEAP1.Oncotarget. 7(18), 25103–25112 (2016).
  MedlineGoogle Scholar
• 44. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody–drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31(10), 589–604 (2015).
  Medline CASGoogle Scholar
• 45. Al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy. Cancer 78(7), 1359–1373 (1996).
  Medline CASGoogle Scholar
• 46. Matulonis UA, Birrer MJ, O'Malley DM et al. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody–drug conjugate mirvetuximab soravtansine. Clin. Cancer Res. 25(6), 1727–1736 (2019).
  Medline CASGoogle Scholar
• 47. Thon JN, Devine MT, Begonja AJ et al. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood. 120(10), 1975–1984 (2012).
  Medline CASGoogle Scholar
• 48. Zhao H, Gulesserian S, Malinao MC et al. A potential mechanism for ADC-induced neutropenia: Role of neutrophils in their own demise. Mol. Cancer Ther. 16(9), 1866–1876 (2017).
  Medline CASGoogle Scholar
• 49. Uppal H, Doudement E, Mahapatra K et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin. Cancer Res. 21(1), 123–133 (2015).
  Medline CASGoogle Scholar
• 50. de Goeij BECG, Lambert JM. New developments for antibody–drug conjugate-based therapeutic approaches. Curr. Opin. Immunol. 40, 14–23 (2016).
  Medline CASGoogle Scholar
• 51. Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 17(1), 35–43 (2015).
  Medline CASGoogle Scholar
• 52. Pratt KP. Anti-drug antibodies: Emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity. Antibodies. 7(2),1–18 (2018).
  Google Scholar
• 53. Chalouni C, Doll S. Fate of antibody–drug conjugates in cancer cells. J. Exp. Clin. Cancer Res. 37(1), 1–12 (2018).
  MedlineGoogle Scholar
• 54. Zhang S, Zhou D, Zheng C et al. Preclinical evaluation of a novel antibody–drug conjugate targeting DR5 for lymphoblastic leukemia therapy. Mol. Ther. Oncolytics 21(908), 329–339 (2021).
  MedlineGoogle Scholar
• 55. Meyer DW, Bou LB, Shum S et al. An in vitro assay using cultured Kupffer cells can predict the impact of drug conjugation on in vivo antibody pharmacokinetics. Mol. Pharm. 17(3), 802–809 (2020).
  Medline CASGoogle Scholar
• 56. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19(13), 3244–3254 (2001).
  Medline CASGoogle Scholar
• 57. Palanca-Wessels MCA, Czuczman M, Salles G et al. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 16(6), 704–715 (2015).
  Medline CASGoogle Scholar
• 58. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812–1821 (2010).
  Medline CASGoogle Scholar
• 59. European Society for Medical Oncology. FDA approves ado-trastuzumab emtansine for early breast cancer (2019). https://www.esmo.org/oncology-news/fda-approves-ado-trastuzumab-emtansine-for-early-breast-cancer
  Google Scholar
• 60. Deonarain MP, Yahioglu G, Stamati I, Marklew J. Emerging formats for next-generation antibody drug conjugates. Expert Opin. Drug Discov. 10(5), 463–481 (2015).
  Medline CASGoogle Scholar
• 61. Mokhtari RB, Homayouni TS, Baluch N et al. Combination therapy in combating cancer. Oncotarget 8(23), 38022–38043 (2017).
  MedlineGoogle Scholar
• 62. Boshuizen J, Koopman LA, Krijgsman O et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody–drug conjugate and BRAF/MEK inhibitors. Nat. Med. 24(2), 203–212 (2018).
  Medline CASGoogle Scholar